European Union - English - EMA (European Medicines Agency)

csl behring gmbh - human coagulation factor viii, human von willebrand factor - hemophilia a; von willebrand diseases - blood coagulation factors, von willebrand factor and coagulation factor viii in combination, antihemorrhagics - von willebrand disease (vwd)prophylaxis and treatment of haemorrhage or surgical bleeding in patients with vwd, when desmopressin (ddavp) treatment alone is ineffective or contraindicated.haemophilia a (congenital factor-viii deficiency)prophylaxis and treatment of bleeding in patients with haemophilia a.

United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - von willebrand factor human (unii: ze22ne22f1) (von willebrand factor human - unii:ze22ne22f1) - von willebrand factor human 650 [iu] in 5 ml - vonvendi [von willebrand factor (recombinant)] is a recombinant von willebrand factor (rvwf) indicated for use in adults (age 18 and older) diagnosed with von willebrand disease (vwd) for: - on-demand treatment and control of bleeding episodes. - perioperative management of bleeding. - routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe type 3 vwd receiving on-demand therapy. vonvendi is contraindicated in patients who have had life-threatening hypersensitivity reactions to vonvendi or constituents of the product (tri-sodium citrate-dihydrate, glycine, mannitol, trehalose-dihydrate, polysorbate 80, and hamster or mouse proteins) [see description (11)] . risk summary adequate and well-controlled studies with vonvendi have not been conducted in pregnant women. animal developmental and reproductive toxicity studies have not been conducted with vonvendi. it is not known whether vonvendi can cause fetal harm when administered to a pregnant woman or whether it can affect reprodu

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 1000 iu; von willebrand factor, quantity: 2400 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - von willebrand factor, quantity: 1200 iu; factor viii, quantity: 500 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 500 iu; von willebrand factor, quantity: 1200 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 250 iu; von willebrand factor, quantity: 600 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.

Israel - English - Ministry of Health

csl behring ltd., israel - factor viii (human); von willebrand factor - powder and solvent for solution for injection/infusion - factor viii (human) 1000 iu / 15 ml; von willebrand factor 2400 iu / 15 ml - coagulation factor viii - coagulation factor viii - congenital and acquired deficiency of blood clotting factor viii: severe or moderate haemophilia,prophylaxis during operation, von willebrands disease.

Israel - English - Ministry of Health

csl behring ltd., israel - factor viii (human); von willebrand factor - powder and solvent for solution for injection/infusion - factor viii (human) 250 iu / 5 ml; von willebrand factor 600 iu / 5 ml - coagulation factor viii - coagulation factor viii - congenital and acquired deficiency of blood clotting factor viii: severe or moderate haemophilia, prophylaxis during operation, von willebrand's disease.

Malta - English - Medicines Authority

takeda manufacturing austria ag industriestrasse 67, a-1221, vienna, austria - factor viii, human, von willebrand - powder and solvent for solution for injection - factor viii, human 250 iu von willebrand factor, human 190 iu - antihemorrhagics

Malta - English - Medicines Authority

takeda manufacturing austria ag industriestrasse 67, a-1221, vienna, austria - factor viii, human, von willebrand - powder and solvent for solution for injection - factor viii, human 500 iu von willebrand factor, human 375 iu - antihemorrhagics